NEU neuren pharmaceuticals limited

Share Price, page-13289

  1. 2,645 Posts.
    lightbulb Created with Sketch. 786
    Hard to value?

    1,620m (Market Cap) - 210m (Cash as of 30th September) - 50m (Cash from Milestone Payment = 1.36b~ EV.

    We are going to earn between 216-218m in net income. Our expenses in H1 include R&D was 20m, so our full year expenses are likely to be 40m~. That is 176m pre-tax profit.

    That is a forward PE of 7.40~ on 2024 numbers and 6.4~ trailing on pre-tax earnings.

    Note: pre-tax (2023 was 205m pre tax profit, 157m NPAT)

    Yes there are impacts of one off in that equation but there are still plenty one-off payments due to be paid over the next few calendar years, particulary when ACAD expands Daybue into RoW.

    And what is the value for NNZ-2591 in this equation? right now it's a a negative value - even with the most conservative of estimates. We also have no debt, and our product is the only approved product but there's zero credit given in our valuation.
    Last edited by htae39: 21/11/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$17.55
Change
0.540(3.17%)
Mkt cap ! $2.211B
Open High Low Value Volume
$17.48 $18.44 $17.40 $16.43M 922.3K

Buyers (Bids)

No. Vol. Price($)
4 2624 $17.53
 

Sellers (Offers)

Price($) Vol. No.
$17.70 1000 1
View Market Depth
Last trade - 16.10pm 07/08/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.